Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144417 · ClinicalTrials.gov registry record · Phase 2
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
A Phase 2 study of Tuberculosis, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 433
- Enrollment target
- 20
- Study locations
NCT00144417 is a Phase 2 study of Tuberculosis that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 433 participants, below the 919-participant average among 29 other Tuberculosis trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00144417, a Phase 2 study of Tuberculosis, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 433 participants
- Enrollment target
- 20
- Study locations
Study Summary
This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.
Conditions Studied
Interventions
- DRUG Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)
- DRUG isoniazid
Study Locations (20)
California
- University of Southern California Medical Center - Los Angeles
- University of California at San Diego - San Diego
- University of California, San Francincisco - San Francisco
Texas
- University of North Texas Health Science Center - Fort Worth
- Houston Veterans Administration Medical Center - Houston
- Audie L Murphy Memorial Veterans Administration Medical Center - San Antonio
Illinois
- Northwestern University - Chicago
- Hines Veterans Administration Medical Center - Hines
New York
- Columbia University - New York
- Harlem Hospital, Columbia University - New York
Arkansas
- Veterans Administration Medical Center of Arkansas - Little Rock
Colorado
- Denver Public Health Department - Denver
District of Columbia
- Washington DC Veterans Administration Medical Center - Washington D.C.
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144417
The ClinicalTrials.gov registry entry for NCT00144417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 433 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 919-participant average among 29 other Tuberculosis trials with a reported enrollment target (53% lower). The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 2 interventions - of which Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) is the first listed.
NCT00144417 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT00144417 about?
NCT00144417 is a clinical study titled "TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment". This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.
What is the current status of trial NCT00144417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 433 participants. The study started on 2006-02. Estimated completion is 2007-12.
What conditions does trial NCT00144417 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT00144417?
The interventions under investigation include: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) (DRUG), isoniazid (DRUG).
Who is sponsoring clinical trial NCT00144417?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144417 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
COMPLETED · Phase 2
-
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
COMPLETED · Phase 2
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.